NEU1 is more abundant in uveitic retina with concomitant desialylation of retinal cells

Author(s):  
Lea Lorenz ◽  
Barbara Amann ◽  
Sieglinde Hirmer ◽  
Roxane L Degroote ◽  
Stefanie M Hauck ◽  
...  

Abstract Desialylation of cell surface glycoproteins carried out by sialidases affects various immunological processes. However, the role of neuraminidase 1 (NEU1), one of the four mammalian sialidases, in inflammation and autoimmune disease is not completely unraveled to date. In this study, we analyzed the retinal expression of NEU1 in equine recurrent uveitis (ERU), a spontaneous animal model for autoimmune uveitis. Mass spectrometry revealed significantly higher abundance of NEU1 in retinal Müller glial cells (RMG) of ERU-diseased horses compared to healthy controls. Immunohistochemistry uncovered NEU1 expression along the whole Müller cell body in healthy and uveitic states and confirmed higher abundance in inflamed retina. Müller glial cells are the principal macroglial cells of the retina and play a crucial role in uveitis pathogenesis. To determine whether higher expression levels of NEU1 in uveitic RMG correlate with the desialylation of retinal cells, we performed lectin-binding assays with sialic acid-specific lectins. Through these experiments, we could demonstrate a profound loss of both α2-3- and α2-6-linked terminal sialic acids in uveitis. Hence, we hypothesize that the higher abundance of NEU1 in uveitic RMG plays an important role in the pathogenesis of uveitis by desialylation of retinal cells. As RMG become activated in the course of uveitis and actively promote inflammation, we propose that NEU1 might represent a novel activation marker for inflammatory RMG. Our data provide novel insights in the expression and implication of NEU1 in inflammation and autoimmune disease.

Redox Biology ◽  
2019 ◽  
Vol 24 ◽  
pp. 101199 ◽  
Author(s):  
Soumya Navneet ◽  
Jing Zhao ◽  
Jing Wang ◽  
Barbara Mysona ◽  
Shannon Barwick ◽  
...  

Neuroscience ◽  
2003 ◽  
Vol 122 (1) ◽  
pp. 229-235 ◽  
Author(s):  
C Harada ◽  
T Harada ◽  
H.-M.A Quah ◽  
F Maekawa ◽  
K Yoshida ◽  
...  

2022 ◽  
Author(s):  
Caryn E Plummer ◽  
Timothy Polk ◽  
Jatin Sharma ◽  
Sarah Bae ◽  
Olivia Barr ◽  
...  

Abstract Equine recurrent uveitis (ERU) is a painful and debilitating autoimmune disease, and represents the only spontaneous model of human recurrent uveitis (RU). Despite the efficacy of existing treatments, RU remains a leading cause of visual handicap in horses and humans. Cytokines, which utilize Janus kinase 2 (Jak2) for signaling, drive the inflammatory processes in ERU that promote blindness. Notably, suppressor of signaling-1 (SOCS1), which naturally limits the activation of Jak2 through binding interactions, is often deficient in autoimmune disease patients. Significantly, we previously showed that topical administration of a SOCS1 peptide mimic (SOCS1-KIR) mitigated induced rodent uveitis. In this pilot study, we test the potential to translate the therapeutic efficacy observed in experimental rodent uveitis to equine patient disease. Through bioinformatics and peptide binding assays we demonstrate putative binding of the SOCS1-KIR peptide to equine Jak2. We also show that topical, or intravitreal injection of SOCS1-KIR was well tolerated within the equine eye through physical and ophthalmic examinations. Finally, we show that topical SOCS1-KIR administration was associated with significant clinical ERU improvement. Together, these results provide a scientific rationale, and supporting experimental evidence for the therapeutic use of a SOCS1 mimetic peptide in RU.


PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0183775 ◽  
Author(s):  
Tomoka Ishida ◽  
Takeshi Yoshida ◽  
Kosei Shinohara ◽  
Kejia Cao ◽  
Ken-ichi Nakahama ◽  
...  

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11316
Author(s):  
Sandra Sagmeister ◽  
Juliane Merl-Pham ◽  
Agnese Petrera ◽  
Cornelia A. Deeg ◽  
Stefanie M. Hauck

Background The underlying pathomechanisms in diabetic retinopathy (DR) remain incompletely understood. The aim of this study was to add to the current knowledge about the particular role of retinal Müller glial cells (RMG) in the initial processes of DR. Methods Applying a quantitative proteomic workflow, we investigated changes of primary porcine RMG under short term high glucose treatment as well as glycolysis inhibition treatment. Results We revealed significant changes in RMG proteome primarily in proteins building the extracellular matrix (ECM) indicating fundamental remodeling processes of ECM as novel rapid response to high glucose treatment. Among others, Osteopontin (SPP1) as well as its interacting integrins were significantly downregulated and organotypic retinal explant culture confirmed the selective loss of SPP1 in RMG upon treatment. Since SPP1 in the retina has been described neuroprotective for photoreceptors and functions against experimentally induced cell swelling, it’s rapid loss under diabetic conditions may point to a direct involvement of RMG to the early neurodegenerative processes driving DR. Data are available via ProteomeXchange with identifier PXD015879.


1974 ◽  
Vol 249 (6) ◽  
pp. 1769-1780
Author(s):  
Bruce K. Schrier ◽  
Edward J. Thompson
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document